FDA Commissioner Marty Makary leaves post after about 13 months in office
The facts
- Marty Makary left his position as commissioner of the Food and Drug Administration on May 12.
- Makary had served as FDA commissioner for a little over a year, with several reports describing his tenure as about 13 months.
- President Donald Trump publicly said Makary was leaving and described him to reporters as a "terrific guy."
- Multiple reports said Makary's departure followed pressure and disputes over FDA policy, including criticism tied to flavored vape approvals and to abortion-pill policy.
- Kyle Diamantas, an FDA deputy commissioner, is expected to lead the agency in an acting capacity after Makary's departure.
- Makary's exit is part of broader turnover in the federal health leadership under the Trump administration and HHS Secretary Robert F. Kennedy Jr.
- The leadership change matters because the FDA oversees regulation of drugs, medical devices, food safety and related health products, and the agency is now operating under interim leadership while a permanent successor is chosen.
- It remains unresolved whether Makary resigned entirely on his own or was effectively pushed out, as reports described both a resignation and prior White House approval of a plan to remove him.
Context
Who is running the FDA now?
Reports say Kyle Diamantas, an FDA deputy commissioner, will serve as acting commissioner following Makary's departure Medscape,Guardian,Fox News.
Common ground, and where they split
- Common ground
- An agency with sweeping authority over drugs, devices, food safety and other health products is now under interim leadership after a contested departure, and neither framing treats that kind of uncertainty at the FDA as trivial.
- Where Left and Right split
- Less a disagreement than a question of emphasis: the risk that broader health-leadership churn weakens steady public-health oversight, versus the need for a clear, disciplined account of whether the commissioner resigned or was effectively pushed out.
How left and right read it
What stands out is the instability at an agency that regulates drugs, medical devices, food safety and other health products. Makary’s departure after reported pressure over flavored vape approvals and abortion-pill policy, amid broader turnover in federal health leadership, leaves the FDA under interim leadership at a moment when steady public-health oversight matters.
The central issue is procedural clarity and institutional discipline. Reports say Makary both resigned and may have been subject to a previously approved plan to remove him, so with the FDA now under acting leadership, the administration owes a clear account of how this change was handled at an agency with major regulatory power.
The receipts — 100 sources
Wire services (7)
Other coverage (93)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.